Virus-like particles identify an HIV V1V2 Apex-1 binding neutralizing antibody that lacks a protruding loop by Cale, Evan M et al.
 1 
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing 1 
Antibody that Lacks a Protruding Loop  2 
 3 
Evan M. Cale1,10, Jason Gorman1,10, Nathan A. Radakovich1, Ema T. Crooks2, Keiko Osawa2, 4 
Tommy Tong2, Jiaqi Li1, Raju Nagarajan3, Gabriel Ozorowski4, David R. Ambrozak1, Mangai 5 
Asokan1, Robert T. Bailer1, Anthony K. Bennici1, Xuejun Chen1, Nicole A. Doria-Rose1, 6 
Aliaksandr Druz1, Yu Feng5, M Gordon Joyce1, Mark K. Louder1, Sijy O’Dell1, Courtney Oliver1, 7 
Marie Pancera1, Mark Connors6, Thomas J. Hope7, Thomas B. Kepler8, Richard T. Wyatt5, 8 
Andrew B. Ward4, Ivelin S. Georgiev3,9,  9 
Peter D. Kwong1,*, John R. Mascola1,+, James M. Binley2, #,‡ 10 
 11 
1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National 12 
Institutes of Health, Bethesda, MD 20892, USA 13 
2San Diego Biomedical Research Institute, San Diego, CA 92121, USA 14 
3Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA 15 
4Department of Integrative Structural and Computational Biology, The Scripps Research Institute, 16 
La Jolla, CA 92037, USA 17 
5Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 18 
92037, USA 19 
6HIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and 20 
Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA 21 
7Department of Cell and Molecular Biology, Feinberg Medical School, Northwestern University, 22 
Chicago, IL 60611, USA 23 
8Boston University Department of Microbiology, Boston, MA 02118, USA 24 
9Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 25 
Nashville, TN 37232, USA 26 
10#Lead contact 27 




Most HIV-1-specific neutralizing antibodies isolated to date exhibit unusual characteristics that 31 
complicate their elicitation. Neutralizing antibodies that target the V1V2 apex of the HIV-1 32 
envelope (Env) trimer feature unusually long protruding loops, enabl them to penetrate the HIV-1 33 
glycan shield. As antibodies with loops of requisite length are created through uncommon 34 
recombination events, an alternative mode of apex binding has been sought. Here, we isolated a 35 
lineage of Env apex-directed neutralizing antibodies, N90-VRC38.01-11, using virus-like particles 36 
and conformationally stabilized Env trimers as B cell probes. A crystal structure of N90-VRC38.01 37 
with a scaffolded V1V2 revealed a binding mode involving side-chain to side-chain interactions 38 
that reduced the distance the antibody loop must traverse the glycan shield, facilitating V1V2 39 
binding via a non-protruding loop. The N90-VRC38 lineage identifies a solution for V1V2apex 40 
binding that provides a more conventional B cell pathway for vaccine design. 41 
 42 
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 Neutralizing antibodies (NAbs) are likely to be a key component of effective HIV-1 vaccine 48 
immunity (Mascola and Montefiori, 2010). NAbs interfere with HIV-1 infection by binding to 49 
envelope (Env) spikes (comprised of gp120/gp41 trimers) on virion surfaces, thereby blocking 50 
receptor engagement and/or membrane fusion (Overbaugh and Morris, 2012). The glycan shield 51 
encasing these trimers helps the virus to evade NAbs, in part because carbohydrates are self-52 
antigens to which antibody (Ab) responses are likely regulated by tolerance. Nevertheless, most, 53 
if not all, broadly neutralizing antibodies (bnAbs) make some glycan contacts upon native Env 54 
trimer binding (Stewart-Jones et al., 2016). 55 
 HIV-1 vaccine candidates can induce autologous NAbs but largely fail to induce NAbs 56 
against other circulating (tier 2) strains (Crooks et al., 2015; de Taeye et al., 2015; McCoy and 57 
Weiss, 2013). In contrast, cross-reactive NAbs develop in ~50% of HIV-1 infections (Doria-Rose 58 
et al., 2010; Hraber et al., 2014). Isolating monoclonal NAbs from such donors affords 59 
opportunities to understand how they develop and may be useful as vaccine blueprints (Burton 60 
and Hangartner, 2016). 61 
 Monoclonal bnAbs fall into several epitope clusters that, together, cover most of the trimer 62 
surface (Pancera et al., 2014; Ward and Wilson, 2015). The consistent features in different bnAbs 63 
suggest that a limited number of repertoire solutions can effectively tackle this complex antigen 64 
(Kwong and Mascola, 2012; Mascola and Haynes, 2013). One group of bnAbs targets the gp120 65 
V1V2 loop at the trimer apex and includes PG9/16, CH01-04, CAP256.VRC26.01-33, and 66 
PGT141-145/PGDM1400-1412 (Andrabi et al., 2015; Bonsignori et al., 2011; Doria-Rose et al., 67 
2015; Doria-Rose et al., 2014; Gorman et al., 2016; McLellan et al., 2011; Moore et al., 2011; 68 
Pancera et al., 2010; Sok et al., 2014; Walker et al., 2011; Walker et al., 2009). These NAbs 69 
exhibit unusually long (>24 amino acid (AA) by Kabat numbering) anionic third heavy chain 70 
complementarity determining regions (CDRH3) that are often tyrosine sulfated (excluding CH01-71 
04) and project outward to penetrate the glycan shield and contact underlying protein. Abs with 72 
long CDRH3s naturally occur at low frequency due to a need for unusual recombination events 73 
and their regulation by tolerance (Briney et al., 2012a; Briney et al., 2012b; Haynes et al., 2012). 74 
Therefore, one goal of ongoing bnAb discovery is to identify NAbs with common repertoire 75 
features that are amenable to vaccine design. 76 
 NAb recovery efforts have taken two approaches. One involves high throughput screening 77 
of memory B cell micro-cultures that identified known V1V2-directed bnAbs (Bonsignori et al., 78 
2011; Doria-Rose et al., 2014; Walker et al., 2011; Walker et al., 2009). A second approach is to 79 
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label desirable memory B cells with fluorescent "baits", followed by single cell sorting and RT-80 
PCR (Doria-Rose et al., 2015; Kong et al., 2016; Sok et al., 2014). Here virus-like particles (VLPs) 81 
that present trimers in a natural membrane context (Crooks et al., 2015; Crooks et al., 2011; Hicar 82 
et al., 2010) to probe memory B cells of a donor whose serum exhibited broad neutralization. We 83 
recovered a NAb lineage of moderate potency and breadth, N90-VRC38.01-11, that bound the 84 




VLPs dentify a ew NAb ineage with an verage ength CDRH3 88 
To develop B cell probe, we co-transfected plasmids encoding SIV Gag, Env, Rev and 89 
Gag-GFP (Figure S1). Concentrated supernatants were protease digested, resulting in “GFP-90 
Trimer VLPs”. SIV Gag and Gag-RFP plasmids were co-transfected to make “RFP-bald VLPs” as 91 
a counterstain. VLP labeling was verified using monoclonal Ab (mAb)-expressing Ramos cells 92 
and primary seronegative B cells (Figure S1). VLPs were then used to probe donor N90 B cells, 93 
whose serum neutralizes in a pattern that not track with known bnAbs (Georgiev et al., 2013; 94 
Huang et al., 2014) (Figure S2A). Negatively-selected N90 memory B cells were stained and 95 
gated for singlets, CD3-, CD8-, CD14-, CD19+, IgG+, GFP+ and RFP- (Figure S). The extended 96 
positive shoulder imparted by trimer VLP suggested specific labeling. We selected cells shown 97 
as green dots (Figure 1B). Despite a study in which VLPs recovered lipid binding Abs (Hicar et 98 
al., 2010), RFP-bald VLP counterstaining was weak. The difference could relate to the higher VLP 99 
dose used for staining that allowed stringent washing (Figures S1C and S1D), but may also relate 100 
to the relatively dim RFP signal (Figure S1F). Following cell lysis, heavy and light chain variable 101 
segments were RT-PCR amplified, sequenced and aligned. We prioritized clones with NAb 102 
features: i) >10% divergence from germline VH (heavy chain variable domain) nucleotide 103 
sequence, ii) long CDRH3 loops, iii) repeated recovery and iv) insertion and deletion mutations. 104 
Two related clones, VRC38.01 and VRC38.02 (dark green dots in Figure 1B), were identified. 105 
 To recover VRC38 relatives, a second sort used PE-labeled BG505 SOSIP gp140 trimers 106 
(a near native Env ectodomain mutant derived from the BG505 strain) as a positive probe. As 107 
VRC38.01 neutralizes the HIV-1 strain YU2 but does not bind to gp140F (a non-native, uncleaved 108 
Env ectodomain bearing a C-terminal foldon trimerization tag) derived from the same strain by 109 
ELISA (Figures S2D and S2E), APC-labeled YU2 gp140F trimers were used as a counterstain. 110 
PE+APC- sorting (Figure S) recovered 9 more variants, VRC38.03-11 (dark red dots in Figure 1C), 111 
all of which show little or no gp140F binding (Figures S S). 112 
VRC38 variants had a 16 AA CDRH3 and a 10 AA CDRL3, diverged 15-20% nucleotide 113 
from germline VH3-13 (Figure 1D) and neutralized 3-42% of a multi-clade 31-member virus panel 114 
(Figure 1E). Geometric mean IC50 titers (GMT) against sensitive viruses were 0.076-1.62 µg/ml. 115 
Although VRC38.09 was not as broad as VRC38.01, it neutralized one VRC38.01-resistant virus 116 
(X1632.S2.B10) (Figures 1E and S2A). We paired 3 VRC38 heavy chain orphans from the second 117 
sort (Figure S2B) with the VRC38.01 light chain, one of which, VRC38.14, neutralized a 118 
VRC38.01-resistant strain (ZA012.29). Combining all lineage members, breadth against the 31-119 
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member virus panel was 48%. The broadest clone, VRC38.01 neutralized 30% of a panel of 208 120 
Env-pseudoviruses () and did not react with host antigens, as measured byHep2 (human epithelial 121 
type 2) staining (Figure S). Despite the donor’s North American origin and clade B infection (Wu 122 
et al., 2012), VRC38 NAbs potently neutralized several clade A and AE viruses. 123 
Neutralization profiles (Figure S2A) suggested that VRC38-like NAbs were not a dominant 124 
contributor to serum breadth. Several viruses were sensitive to the N90 serum but not to VRC38 125 
clones. Purified N90 serum immunoglobulin G (IgG) did not compete with VRC38.01 for binding 126 
to JR-FL NFL trimers (Figure S2C), further suggesting low prevalence (<1µg/ml; Figure S2C). 127 
Overall, the VRC38 lineage was  in the donor, exhibited 15-20% germline divergence, modest 128 
neutralization potency and breadth and no autoreactivity. 129 
 130 
VRC38 argets the V1V2-trimer pex 131 
 VRC38.01's ability to neutralize the YU2 strain (Figure 1E), despite poor YU2 gp140F 132 
binding (Figures S and S), suggested a quaternary epitope. By ELISA, VRC38.01 competed 133 
strongly with V1V2 bnAbs for binding trimer VLPs and, to a lesser extent, with glycan-V3 bnAb 134 
PGT121 (Figure 2A). Reciprocally, V1V2 bnAbs, PGT121 and to a modest extent, glycan-V3 135 
bnAb PGT125 inhibited VRC38.01 binding (Figure SA). Neutralization of the JR-FL strain without 136 
a E168K mutation (Figure 1E), suggested a distinct V1V2 binding mode. nlike VRC38.01, this 137 
mutation was crucial for other V1V2 NAbs, and in some cases (PG9, PG16 and CH01)  N189A 138 
mutation was also needed for full sensitivity (Figure SB) (Doores and Burton, 2010). 139 
  To assess quaternary epitope dependency, we compared binding to monomeric gp120 140 
and trimeric SOSIPs of sensitive strains, Q23.17 and DU156.12. Like PGT145, VRC38.01 bound 141 
to trimers but not monomers, whereas glycan-V3 bnAb PGT128 bound to forms of Env (Figure 142 
2B). PG9 bound to DU156.12 but not Q23.17 gp120 (Figure 2B). Further analysis revealed 143 
VRC38.01 and PG9 bound to gp120 monomers from several neutralization-sensitive strains 144 
(Figure 2C). Together, this data suggests that exhibit quaternary epitope preference, but that this 145 
is not a strict requirement for binding. 146 
The footprint of VRC38.01 Fab (fragment, antigen-binding) was examined on BG505 147 
SOSIP trimers by negative-stain electron microscopy (EM, Figure 2D). 2D class averages showed 148 
binding near the trimer apex. PG9 and CAP256.09, for which 3D reconstructions available 149 
(EMDB-2241 and EMDB-5856, respectively) appeared to straddle  gp120 protomers, binding 150 
adjacent to the 3-fold axis at a slightly off vertical angle. 2D views of complexes with Fabs 151 
PDGM1400 or VRC38.01 were insufficient for 3D modeling. Nevertheless, class averages 152 
suggested footprints indicated in Figure 2D. VRC38.01's footprint was farther from the 3-fold axis 153 
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and showed little protomer overlap. Overall, this data showed that VRC38.01 targets the V1V2 154 
apex with a quaternary epitope preference. 155 
 156 
VRC38.01 inds “off center” at ess than 3:1 toichiometry 157 
V1V2 bnAbs typically bind the trimer with a stoichiometry of 1:1, in part because their 158 
footprints straddle gp120 protomers. 2D class averages of VRC38.01 Fab-trimer complexes by 159 
EM indicated 1 or 2 Fabs per trimer in ~85% or ~15% of cases, respectively (Figure 2D). Using 160 
VRC38.01 IgG, rather than the Fab, increased the proportion of complexes containing two Abs to 161 
65% (Figure 2D), perhaps due to the increased avidity of two Fab arms; however, as the 162 
crystallizable (Fc) of the IgGs was unresolved, it was unclear whether both Fabs originated from 163 
the same IgG in the images. Related to this point, VRC38.01 IgG was much more potent (17- to 164 
170-fold) than its monovalent Fab, unlike PG9 (1- to 3.5-fold higher) and PGT145 (1- to 12-fold 165 
higher) (Figure SA). Furthermore, real time binding of VRC38.01 IgG to BG505 SOSIP trimers 166 
showed >7-fold stronger binding over the Fab (Figure SB), also supporting the idea that 167 
VRC38.01 IgG may engage trimers with both Fab arms simultaneously. 168 
  stoichiometry was investigated by three further methods. First, we checked bnAb-169 
mediated native trimer mobility shifts. 2G12 bound progressively to trimers with increasing 170 
concentrations, providing a reference ladder (Figure SC). Saturating concentrations of all V1V2 171 
NAbs bound at one copy per trimer (Figure SC). In a second approach, we measured binding 172 
kinetics by biolayer interferometry (BLI). A standard curve was first generated with various trimer-173 
NAb complexes of known ligand stoichiometries at saturation (Figure SD). By interpolation, we 174 
inferred that ~2 copies of VRC38.01 (Fab or IgG) occupied the trimer (Figure SD). In a third 175 
approach, we performed isothermal titration calorimetry (ITC) to assess VRC38.01 Fab binding 176 
to the BG505 native, flexibly linked (NFL) trimer, resulting in an estimate of N=2.26 (Figure SE). 177 
Previously, one copy PG9 Fab resulted in N=0.6–0.8 (Julien et al., 2013; Sanders et al., 2013), 2 178 
copies of PGT151 Fab resulted in N=1.3 (Blattner et al., 2014) and 3 copies of PGT121 or 2G12 179 
Fabs binding per trimer gave N=2.3–2.4 (Sanders et al., 2013). Thus, an N value of 2.26 suggests 180 
that 2-3 VRC38.01 Fabs bind per trimer. 181 
 he discrepancies above may relate to assay , with negative-stain EM and BN-PAGE 182 
emphasizing binding at equilibrium and BLI and ITC emphasizing on rate and maximum binding. 183 
Another contributing factor may be that the trimer strain and form differed between assays. Similar 184 
discrepancies were previously noted (Lee et al., 2015). Collectively, our data suggest sub-trimer 185 
(Figures 2D and S). 186 
 187 
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VRC38.01 argets V1V2 pex lycans ia a on-rotruding oop 188 
The off-center VRC38.01 footprint (Figure 2D), and its ability to neutralize viruses lacking 189 
a K168 residue (Figure SB) suggested a unique binding mode. To obtain atomic ,  a V1V2-1FD6 190 
scaffold. For reference, we first determined the unliganded VRC38.01 Fab structure to 1.6 Å, then 191 
solved the complex structure to 3.5 Å by molecular replacement. Refinement yielded an Rwork/Rfree 192 
of 17.3/20.2 and 23.8/28.2 for the unliganded Fab and co-crystal structures, respectively (Figures 193 
3A-C, S, Table S). No significant binding-induced conformational changes were observed 194 
(Figures 3B, 3C and S5A). Overall, these structures revealed V1V2 loop binding via protein-195 
protein side-chain interactions with strands A, B and C and extensive N156 and N160 glycan 196 
binding (Figures 3 and S). 197 
The V1V2 domain formed a 5-stranded ß-barrel as for near-native BG505 Env trimers 198 
(Pancera et al., 2014; Stewart-Jones et al., 2016), with a root-mean-square deviation (rmsd) of 199 
1.1 Å across the ß-strand residues (Figure 3C). Extensive VRC38.01-N-linked glycan contacts 200 
had buried surface areas of 465 Å2 and 573 Å2 for N156 and N160 glycans, respectively, each 201 
contributing a hydrogen bond (Figure 3D-E). Mutations revealed that VRC38.01 was critically 202 
dependent on glycan N156 and heavily depended on glycan N160 (Figure S). Minor contacts 203 
were observed between the light chain and glycan N133 (Figures 3A and 3E). Protein-protein 204 
contacts accounted for 1,135Å2 of buried surface area. Seven hydrogen bonds were observed, 205 
six from the heavy chain and one from the light chain (Figure S). 206 
Alignment of the complex to trimeric Env via the V1V2 (Figure 3F) confirmed the off-center 207 
footprint seen by EM (Figure 2D). Although direct VRC38.01 inter-protomer interactions were not 208 
observed, the Fab aligned closely to the N160 glycan of a neighboring gp120 protomer and the 209 
9-residue disordered loop between positions N185 and S187 (Figure S). To probe these potential 210 
quaternary interactions, we engineered a glycan into the scaffold to mimic the neighboring N160 211 
(scaffold insert position is shown in Figure 4I). Although electron density observed for this 212 
engineered glycan was distal from the VRC38.01 epitope (Figure S),  N160 positioning is not 213 
precise, we rule out this interaction on the trimer. However,  VRC38.01 binds monomeric gp120 214 
of several strains, N160 glycan binding is probably not essential. The nine AAs following residue 215 
185 in gp120 are disordered in available trimer structures and proximal to the framework 3 and 216 
CDRH1 of VRC38.01 (). However, mutagenesis suggested that this region did not affect 217 
VRC38.01, although CH01 and PGT145 were adversely affected by I184A mutations in the 218 
WITO.33 and BG505 strains, respectively, proximal to this region (Figure S). Analysis of the 219 
docked model in Figure 3F suggested that  VRC38.01 Fabs could potentially occupy one HIV-1 220 
trimer with no clashes (overlap cutoff >0.4Å; Figure S). The sub-saturating VRC38.01 221 
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stoichiometry (Figures 2D and S) may therefore stem from glycan and/or trimer structural 222 
heterogeneity (Liao et al., 2013). Based on the distance of the modeled Fab C-termini, VRC38.01 223 
is unique in being potentially able to use both IgG arms to engage the trimer. The large differences 224 
VRC38.01 IgG and Fab neutralization potency (Figure SA) and trimer affinity (Figure SB) lend 225 
indirect support this idea. In summary, the cocrystal reveals N156 and/or N160 glycan-226 
dependence, but also light chain contacts and a possibility to engage the trimer with both IgG 227 
arms. 228 
 229 
VRC38.01 akes idechainidechain ontacts at the V2 pex  VRC38.01 exhibits a near charge-230 
neutral 16 AA CDRH3, unlike other V1V2 NAbs that exhibit unusually long (>24 AA) anionic 231 
CDRH3s (Figure 4A) (Andrabi et al., 2015; Bonsignori et al., 2011; Doria-Rose et al., 2015; 232 
Gorman et al., 2016; McLellan et al., 2011; Walker et al., 2011; Walker et al., 2009). Although 233 
CH01 has greater breadth (53%) than its clonal variant CH03 (42%), we analyzed CH03 (AA 234 
sequence identity 83% in the VH and VL regions), due to the available V1V2-complex structure 235 
(Gorman et al., 2016). A comparison to normal Ab repertoire sequences (Shi et al., 2014) revealed 236 
CDRH3 length within normal range, but other V1V2 NAbs  outliers (Figure 4B). VRC38.01 exhibits 237 
a near-neutral CDRH3 charge, is common in the repertoire (Figure 4C). In contrast, other V1V2 238 
NAb CDRH3 loops are negatively charged due to prevalent Glu and Asp residues and sulfated 239 
tyrosines (Figure 4A, 4E and 4F), which interact with the positively charged strand C (Andrabi et 240 
al., 2015; Bonsignori et al., 2011; Doria-Rose et al., 2015; Gorman et al., 2016; McLellan et al., 241 
2011; Walker et al., 2011; Walker et al., 2009). Like other V1V2 NAbs, VRC38.01 diverged from 242 
its germline (18%; Figure 4A and 4D). 243 
 Inspection of CDRH3-V1V2 contacts revealed VRC38.01 bind a site more distal from the 244 
trimer axis than PG9 and CH03 (Figure 4G), consistent with its footprint (Figure 2D). Like other 245 
V1V2 NAbs, VRC38.01 bound the N156 and N160 glycans of strand B (Figure 4G and S), but 246 
made protein-protein contacts solely through Ab side-chain interactions, in contrast to PG9 and 247 
CH03made extensive main-chain parallel strand-strand interactions with strand C residues 167-248 
171 proximal to the inter-protomer interface (Figures 4H and S). The CDRH3 and CDRH1 loops 249 
of VRC38.01 hydrogen bonded side chains of strands A, B and C, including two salt bridges 250 
formed with residues K168 and K171 of strand C and heavy chain residues D31 and E97, 251 
respectively (Figure 4H). This side chain-dependent binding shortens the distance the CDRH3 252 




VRC38.01 ontacts lycans N156 and N160 and trand C but lashes with lycan N130 256 
VRC38.01 eutralized 30% of a diverse panel of 208 pseudoviruses (Figure S and ) at an 257 
IC50<50 µg/ml, comparable to HJ16 and better than 2G12 (Figure SA). VRC38’s GMT against 258 
the 62 sensitive viruses (0.46 µg/ml) was lower than that of CH03 (0.54 µg/ml), 2G12 (1.56 µg/ml), 259 
b12 (1.00 µg/ml), 2F5 (1.63 µg/ml), and 8ANC195 (0.88 µg/ml) and was the same as HJ16 (0.46 260 
µg/ml) (Figure S6A). VRC38.01 exhibited higher activity against 27 subtype A viruses (), where 261 
breadth and median IC50 were 52% and 0.043µg/ml, respectivelyclade A recombinants. Overall, 262 
VRC38.01 exhibited modest potency and breadth. 263 
Some bnAbs, including PG9 and PGT145, often plateau at <100% neutralization, a 264 
phenomenon attributed in part to Env glycan heterogeneity (Doria-Rose et al., 2015; McCoy et 265 
al., 2015). To see if VRC38.01 exhibits this phenomenon, we determined its maximum % 266 
neutralization (Figure SC) against all 208 virus strains in Figure . To exclude weak neutralization 267 
we only used data where IC50s were <1g/ml. 80% and 72% were neutralized at >90% and 268 
>95%, respectively. Similar patterns were observed for PG9 and PGT145. Sub-saturating 269 
neutralization was somewhat more pronounced for CAP256.25 and was highly prevalent for 270 
CH01, where only 5% of viruses were neutralized at a plateau >95%. In summary, like other 271 
glycan V1V2 NAbs, VRC38.01 exhibits sub-saturating neutralization of some viruses. 272 
An analysis of key V1V2 residues of our 208-member virus panel suggest that its side-273 
chain based binding mode (Figures 4H and 4I) may limit VRC38.01's breadth (Figure 5). Of the 274 
148 VRC38.01-resistant strains, 137 related to variants at positions N130, N156 N160, K/R171 275 
and Y173 (Figure 5A and 5B). Despite the VRC38.01 light chain contact with the poorly conserved 276 
N133 glycan of the WITO.33 strain (Figure 3A and 3E), many N133-lacking viruses were 277 
VRC38.01-sensitive. Variation at positions N160, K/R169 and K/R171 explained all 39 PG9-278 
resistant viruses (Figure S). N156, N160 and K/R171 variants explained most CH03-resistant 279 
viruses, but 47 other resistant strains were unexplained (Figure S). Critical residues became 280 
apparent when resistance mutations  mapped onto mAb complexes (Figure 5C). VRC38.01 281 
sensitivity was enhanced by K/R171 salt bridge with Glu97 of the heavy chain and by Y173 282 
reorient N156 (Figure 5C). Conversely, the N130 glycan appeared to cause a light chain clash 283 
(Figure 5C). PG9 sensitivity was enhanced by glycan binding and by electrostatic interactions 284 
between Lys/Arg169 and Tys100g as well as Lys/Arg171 and Asp100i (Figure SC). CH03 285 
sensitivity was also enhanced via glycan interactions and by a salt bridge formed between 286 
Lys/Arg171 and Glu30 of the heavy chain (Figure SD). 287 
Introducing the N130 glycan into 8 viruses that naturally lack this glycan reduced 288 
VRC38.01 sensitivity of all virusesby >50-fold in 7 cases (Figure 5D), but had less on PG9 and 289 
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even less on PGT145, which neutralized a N130 glycan-bearing DU422.01 mutant more 290 
effectively (Figure 5D). These findings are consistent with the latter bnAbs targeting epitopes 291 
closer to the trimer vertex. Reciprocal removal of the N130 glycan increased VRC38.01 sensitivity 292 
of BaL.26 and 25711-2.4 by >40-fold and CAAN.A2 by >7-fold (Figure 5E). VRC38.01 achieved 293 
47.5% neutralization of strain DU172.17 at 50 g/ml, but did not neutralize the parent virus (Figure 294 
5E). Again, the effect of removing glycan was less pronounced  PG9 and PGT145, and in fact 295 
reduced PG9 sensitivity of the 25711-2.4 strain (Figure 5E). Autologous N90 donor viral 296 
sequences (Wu et al., 2012) exhibited key contacts for VRC38 but had a sequon at N130 (3) and 297 
were therefore VRC38.01-resistant. Upon N130D mutation, VRC38.01 reached 50% 298 
neutralization for 3 of viruses (Figure S7E). For the other 5 viruses tested, we detected increased 299 
VRC38.01 sensitivity that did not reach 50% at 100 g/ml (Figure S). 300 
 Further mapping against strand A, B, and C mutants of the WITO.33 strain (4) revealed 301 
sequon-disrupting S158A, N160K, and T162A mutations in strand B  sensitivity to all four V1V2 302 
NAbs (4).  N156A mutant was  poor infection. Strand C mutations revealed K171 and Y173 critical 303 
for VRC38.01 but less so for other V1V2 NAbs. Analysis of BG505 and JR-CSF.JB strain mutants 304 
indicated similar VRC38.01 contacts (4). However, unlike WITO.33, Y173A mutation rendered 305 
these strains completely PGT145-resistant and K171A mutation rendered JR-CSF but not BG505 306 
resistant to CH01. Overall, complete disruption by K171 or Y173 confirm strand C dependency. 307 
Together, sequence analysis of sensitive and resistant viruses (Figure 5) and mutation analysis 308 
(4) indicated VRC38 resistance  largely explained by a N130 or by key residues at positions 171 309 
and 173, and/or glycans at positions 156 and 160. 310 
 311 
VRC38.01 olerates arge annose ranches 312 
 The glycosylation inhibitor kifunensine prevents trimming of high mannose glycans, 313 
resulting in largely uniform Man9GlcNAc2 structures. Pseudoviruses prepared with this inhibitor 314 
are  resistant to V1V2 bnAbs (Doores and Burton, 2010), perhaps due to changes in apex folding 315 
and/or because of a loss of mAb contacts with glycan sialic acid termini in the absence of this 316 
inhibitor (Amin et al., 2013; Pancera et al., 2013). We found that 83% (PG9), 92% (CH01), 94% 317 
(PGT145) and 69% (CAP256.09) of kifunensine viruses were >4-fold resistant (S), but only 38% 318 
were resistant to VRC38.01. This further distinguishes VRC38.01 from other V1V2 mAbs and is 319 
in line with structural evidence suggesting that it can accommodate large mannose branches. 320 
 321 
Ontogen VRC38 eutraliz 322 
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 A phylogenetic tree of all 11 lineage members was generated, rooted by a common 323 
inferred ancestor (IA, Figure 6A). A variant with germline V-gene and J-gene reverted heavy (gH) 324 
and light (gL) chains, but maintaining the mature CDRH3, was unable to neutralize (Table S1). 325 
However, hybrids consisting of mixed mature and reverted heavy and light chain partners, gHL 326 
and HgL, neutralized 19 and 18 strains of a 208-member panel, respectively (). Fourteen strains 327 
were sensitive to both hybrids, while others were neutralized by only one hybrid, indicating that 328 
both chains contribute to neutralization. When both the gHL and HgL Abs were effective, HgL 329 
potency was generally stronger, suggesting that the mature heavy chain plays a dominant role (). 330 
Overall, this suggests that VRC38 can neutralize ~9% of heterologous strains with no maturation 331 
of the V-gene of one chain. 332 
 VRC38 heavy and light chain maturation was modeled in Figure 6 and Table S6, 333 
respectively. S31D mutation likely occurred early in the VRC38 heavy chain (Figure 6A and boxed 334 
starting at sequence I1 in Figure 6B) and forms a salt bridge with a 97% conserved basic residue 335 
at position 168 (Figure 6C). However, data above (Figure 1E) suggests that, unlike other V1V2 336 
NAbs, this contact is not essential (Figure SB). Indeed, a D31S mutant modestly reduced 337 
neutralization of 11 of the 14 strains tested (Figure 6D). Two exceptions were BG1168.01  was 338 
more sensitive to the D31S mutant and ZA012.29 was insensitive to either the parent mAb o 339 
D31S mutant. 340 
VRC38.01 share a branch with broad lineage members VRC38.07 and .06,  to a S97E 341 
mutation acquired at intermediate I3 (Figure 6A-C), that forms a salt bridge with K171 of strand C 342 
(Figure 6C). E97S reversion reduced VRC38.01 neutralization to a larger degree than the D31S 343 
mutant. The two reversions together led to loss in neutralization, suggesting that both contacts 344 
contribute to VRC38.01 neutralizing activity (Figure 6D). VRC38.09, which is almost as broad as 345 
the three members of the VRC38.01 branch but almost 3-fold lower in potency, lacks the S97E 346 
mutation. However, a S97E mutant increased its potency agains 12 of the 14 strains (Figure 6E). 347 
Exception were uniquely VRC38.09-sensitive strain X1632.S2.B10 (Figure 1E) and the 348 
BG1168.01 strain. The behavior of the latter mirrored the effect of the reciprocal mutation on 349 
VRC38.01 (Figure 6D and E). Overall, VRC38.09’s breadth developed independently from other 350 
clones and the sensitivity of some strains to this variant depend on different somatic mutations. 351 
 352 
VRC38-like NAbs ay e revalent in HIV-nfected onors 353 
 To analyze VRC38-like bnAb prevalence, we used neutralization fingerprinting (Doria-354 
Rose et al., 2017; Georgiev et al., 2013) to delineate bnAb specificities in a cohort of HIV-1 355 
infected donors (Hraber et al., 2014). VRC38-like specificities (Figure 7A) were common, 356 
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appearing in ~20% of plasmas, PG9-like bnAbs. nalysis of the frequency of paired specificities 357 
(Figure 7B) revealed that VRC38-like and PG9-like signals were frequently paired with 10E8-like 358 
bnAbs - more frequently than 10E8-like pairings with other Abs. VRC38-like and PG9-like Abs 359 
also paired with each other, albeit at a much lower frequency than with 10E8. Overall, VRC38-360 




 growing number of recovered bnAbs now cover most of the Envtrimer surface. Many have 364 
unusual features that set a high bar for vaccine design and justify continued efforts to uncover 365 
new specificities. The VRC38 lineage provides a previously unknown solution for V1V2 apex 366 
binding, with potential advantages. Abs with >24 AA CDRH3s result from uncommon 367 
recombination events and, due to their typically autoreactive nature, may not survive B cell 368 
tolerance checkpoints (Briney et al., 2012a; Briney et al., 2012b). In contrast, the length and 369 
charge of the VRC38 CDRH3 is within the normal repertoire range. The lack of CDRH3 tyrosine 370 
sulfation or prevalent anionic side chains further advance VRC38 as a tangible vaccine blueprint, 371 
although this possibility will require formal testing. 372 
 Our fingerprint analysis suggested that VRC38-like Abs may be as prevalent as PGT128-373 
like or PG9-like Abs. We are now mapping donor sera with VRC38-like signals and probing their 374 
B cells. Given its common features, VRC38-like NAbs might have been expected to be even more 375 
. However,  N130 glycan is found in >60% of circulating virusesthe single largest regulator of 376 
VRC38's breadth  prevent VRC38-like bnAb development or facilitate escape. Accommodating 377 
glycan might therefore be a route to improved VRC38 breadth. We are now assessing additional 378 
donors and modifying B cell probe strategy. For example, in a variation of the strategy in Figure 379 
1C, B cells could be gated for positive binding to  bearing a N130 glycan knock in mutation. It may 380 
also be useful to interrogate the N90 donor for VRC38 signatures by NGS and to probe samples 381 
from other donors that exhibit VRC38 fingerprint signatures. In a vaccine setting, N130 clash could 382 
be addressed using priming immunogens bearing a N130 "glycan-hole" (Crooks et al., 2015) to 383 
promote VRC38-like NAb development and boosting with N130 glycan-containing immunogens 384 
to select for clones that can accommodate the glycan and thereby acquire greater breadth. 385 
Feasibility is supported by the observations that CD4bs-specific bnAb N6 evolved greater breadth 386 
by accommodating V5 loop glycans (Huang et al., 2016) and that the PGT121 family gained 387 
breadth by accommodating the N137 glycan (Garces et al., 2015). 388 
 Like other V1V2 NAbs (except PGT145 VH1-8), VRC38 VH3, the most common VH family 389 
in human B cell repertoires. Moreover, like other V1V2 bnAbs, VRC38 VH diverged <20% from 390 
its germline. This contrasts with the higher (~40%) divergence of CD4bs bnAbs, making the V1V2 391 
an attractive vaccine target. Indeed, the marginal protective efficacy observed in the RV144 Thai 392 
vaccine trial was related to V1V2-specific Abs, albeit ones that were non-neutralizing and may 393 
therefore have exerted antiviral pressure by other mechanisms (Liao et al., 2013). 394 
Some VRC38 binding requirements are akin to those of other V1V2 NAbs, including N156 395 
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and N160 glycan-dependen quaternary epitope preference and binding. In several other ways, 396 
however, VRC38 is unique. First, it binds farther away from 3-fold trimer axis and both Fab arms 397 
of VRC38.01 IgG  bind to a single trimer. It also exhibits a different binding mode that depends 398 
on CDRH1, CDRH3 and CDRL1 interactions with side-chains of strands A, B, and C rather than 399 
main-chain interactions. This decreases the distance the CDRH3 must travel to penetrate the 400 
glycan shield. Since these contacts are conserved, VRC38 exhibits moderate breadth. Second, 401 
VRC38’s CDRH3 exhibits a highly aromatic motif consisting of seven AAs (WFYHYYW), allowing 402 
it to  glycans N156 and N160. Its unusual kifunensine resistance, along with structural data, 403 
suggest that it engages these glycans predominantly via their invariant stems. Thus, although 404 
glycan form variations may not affect VRC38, other V1V2 NAbs that depend for example on sialic 405 
acid contacts could be more prone to viral escape due to natural glycovariation (Amin et al., 2013; 406 
Pancera et al., 2013). Alternatively, the larger Man9GlcNAc2 structures promoted by kifunensine 407 
may distort packing at the trimer apex, perhaps impacting inter-protomer binding by some V1V2 408 
bnAbs (Julien et al., 2013), but not VRC38 because it binds largely within one protomer. Unlike 409 
other V1V2 bnAbs (except CH01-CH04), VRC38.01's three HCDR3 tyrosines are not sulfated 410 
and lack anionic character. Specifically, YYDbinding motifs (with both tyrosines carrying charged 411 
sulfates) of PG9 and VRC26 are absent. Thus, unlike other V1V2 bnAbs, VRC38.01 binding is 412 
not heavily dependent on electrostatic interactions. 413 
 Although VRC38.01 depends on residues K171 and Y173 of strand C, its partial K168-414 
independence uniquely allows it to neutralize strains that are insensitive to other V2 mAbs. While 415 
K171 makes a clear electrostatic interaction with VRC38.01, Y173 may indirectly contribute by 416 
reorienting the N156 glycan. The lack of sensitivity of clade D viruses to VRC38.01 is explained 417 
by the fact that they typically lack the critical K/R171 and Y173 contacts. The higher clade A 418 
breadth of VRC38.01 was surprising, considering the donor’s infection with a clade B virus and 419 
North America origin (Wu et al., 2012). However, clade A preference is also true for other V1V2 420 
bnAbs, albeit those derived from African origin. However, although VRC38.01 breadth against 421 
clade A and clade A hybrid viruses was relatively high, it did not exceed that against the infecting 422 
clade B. 423 
 The cells from which the VRC38 lineage was cloned were sampled many years after 424 
infection, making it difficult to trace . A common unmutated ancestor and intermediates were 425 
inferred from the 11 Ab sequences derived from the single time point. eutralization by the  reverted 426 
VRC38.01 Ab and hybrid Abs with mature chains indicated both chains contribute to 427 
neutralization, the heavy chain making a greater contribution. Two affinity matured residues on 428 
the heavy chain (S31D and S97E) that form salt bridges  present in the  broadest clones. The 429 
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neutralizing activity of the gHL variant suggests that while these interactions are not critical, they 430 
increase breadth and potency. 431 
  VRC38.09, neutralized a virus that was insensitive to the VRC38.01 branch. Another virus 432 
was uniquely neutralized by the VRC38.14 variant heavy chain when paired with VRC38.01 light 433 
chain. Combining the number of viruses neutralized by all variants brought the VRC38 lineage 434 
breadth to 48%. It is unclear if a pathway could be found to neutralize these strains (and perhaps 435 
more) by a single VRC38 clone, especially since we only have access to one timepoint in this 436 
donor and thus how the lineage might have evolved. 437 
Our success in recovering VRC38 may in part be due to extensive B cell probe 438 
development. The broadest lineage member, VRC38.01, was identified using trimer VLPs as 439 
probes and others were then isolated using SOSIP trimers. Thus, VLPs may complement the 440 
growing list of B cell probes (Doria-Rose et al., 2015; Kong et al., 2016; Sok et al., 2014; van Gils 441 
et al., 2016). The high frequency of NAb clones in the VLP sort (2 out of 92; 2.2%) was consistent 442 
with specific staining. Nevertheless, certain suboptimal aspects of VLPs could be improved. 443 
Trimer VLPs imparted smeared staining in which VRC38.01 and VRC38.02 were relatively dim 444 
on the GFP axis, as opposed to a clearly separated positive population commonly seen with 445 
soluble SOSIP trimers. We are currently investigating alternative conjugation technologies 446 
(Mengistu et al., 2015) to tag VLPs with brighter fluorophores to enhance positive stain separation 447 
from background. Our observation that VRC38.01 contributes only partially to N90 serum breadth 448 
suggests other bnAbs exist in this donor that we are now trying to recover. 449 
In summary, a VLP probe recovered a VRC38 NAb lineage targeting the trimer apex 450 
without protruding binding loops by a previously unrecognized mechanism involving side-chain to 451 
side-chain interactions that reduced the distance an Ab loop must traverse the glycan shield. The 452 
genetic, functional and structural analysis of this lineage, together with serological fingerprint 453 
analysis, suggest that similar NAbs may be relatively common during HIV-1 infection and may 454 
thus be amenable to vaccine elicitation.  455 
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FIGURE LEGENDS 476 
 477 
Figure 1. Trimer VLP probes identify a NAb lineage of moderate CDRH3 length from an HIV-478 
1-infected donor. A) Overview of VLP-based NAb isolation. Negatively selected CD19+ B cells 479 
labeled with GFP-trimer VLPs and RFP-bald VLPs, then singly indexed sorted for GFP+RFP- B 480 
cells. Immunoglobulin genes were RT-PCR amplified. Desirable sequences were cloned, 481 
expressed and characterized. B) GFP+RFP-IgG+ B cells (green dots) were selected. Dark green 482 
dots indicate VRC38.01 and .02. C) PE+APC-IgG+ B cells (pink dots) were selected from SOSIP-483 
gp140F stains. Red dots indicate VRC38.03-11. D) VRC38 lineage heavy and light chain 484 
sequences were aligned to their closest V-gene and J-gene germline genes. Clones isolated 485 
using VLPs or SOSIP trimers were colored in green and red, respectively. *Mutation frequencies 486 
refer to percent nucleotide sequence divergence from germline V-gene sequences. E) VRC38.01-487 
11 neutralization of a multi-clade virus panel. GMTs of sensitive viruses (IC50<50µg/ml) and 488 
percent of viruses neutralized at IC50<50µg/ml (breadth) are shown. Although VRC38.05 489 
neutralized only one virus, for comparison, this value was included in the "mean IC50" row. 490 
Neutralization assays were repeated 2 times. See also Figures S1-S. 491 
 492 
Figure 2. VRC38.01 a quaternary epitope at the V1V2 apex. A) Excess VRC38.01 was used 493 
to compete with graded concentrations of biotinylated or strepII-tagged mAbs (VRC01 and 494 
35O22) for binding to JR-FL SOS E168K or BG505 (for CAP256.09) trimer VLPs by ELISA. B) 495 
Binding to SOSIP.664 gp140 trimers and monomeric gp120 of strains Q23.17 and DU156.12 by 496 
ELISA. C) Binding to various monomeric gp120s by ELISA. D) Negative-stain EM of VRC38.01-497 
SOSIP.664 complexes. Representative reference-free 2D class averages of known V1V2 bnAbs 498 
(top panel) and VRC38.01 IgG or Fab (bottom panel) complexed with BG505 SOSIP.664. In the 499 
middle panel, a ligand-free SOSIP model (low-pass filtered EM map created from x-ray 500 
coordinates of PDB 4ZMJ) shows various V1V2 bnAb epitopes. PG9 and CAP256.09 Fabs are 501 
shown by EM volumes and PGDM1400 and VRC38.01 footprints are indicated. For VRC38.01 502 
Fab and IgG, proportions of complexes showing 1 Fab or 2 Fabs binding the trimer are shown. 503 
ELISA assays were repeated 2 times. See also Figures S2, S. 504 
 505 
Figure 3. V1V2 scaffold complexes reveal VRC38.01-glycan contacts and “off center” apex 506 
binding. A) A VRC38.01 V1V2-1FD6 scaffold co-crystal was solved at 3.5 Å. The heavy and light 507 
chains are shown in yellow and blue. The V1V2 (residues 126-196) and 1FD6 scaffold are shown 508 
in magenta and grey, respectively. Glycan mannoses are shown in green, and N-509 
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acetylglucosamine moieties are shown in blue. B) CDRs are highlighted for the bound Fab, which 510 
did not vary from the unbound Fab (). C) The V1V2s of the WITO.33 scaffold (magenta) and 511 
BG505 SOSIP.664 trimer (pink, PDBID 4TVP) were aligned with an RMSD of 1.1 Å in the ß-512 
sheets. D) The highly aromatic CDRH3 loop of VRC38.01 is enveloped by N156 and N160 513 
glycans. Underlined CDRH3 AAs are shown in stick representation. E) A quantitative analysis of 514 
the mAb-glycan contacts is shown, with buried surface area of N-acetylglucosamine (blue 515 
squares) and mannose (green circles) residues indicated. F) Alignment of the VRC38.01-V1V2 516 
complex with the BG505 SOSIP trimer structure (4TVP) via the V1V2 domain. See also Figure. 517 
 518 
Figure 4. VRC38.01's non-protuding HCDR3 makes side chain-side chain contacts at the 519 
V2 apex. A) Key features of prototype V1V2 mAbs, including their source, neutralization breadth 520 
(see Figure S6), germline VH gene use and divergence (nucleotide), CDRH3 length, sequence 521 
and net charge. Negatively charged residues are shown in red and sulfated tyrosines are 522 
underlined. Each NAb is color coded throughout. B) V1V2 mAb CDRH3 lengths (indicated by 523 
colored arrows) compared to the naïve Ab repertoire distribution (Shi et al., 2014). C) Net V1V2 524 
NAb CDRH3 charge compared to the naïve Ab repertoire. D) V1V2 mAb germline divergence 525 
compared to the naïve Ab repertoire. E) Alignment of the 5 mAb structures via their framework 526 
regions. F) Sulfated tyrosines are shown as sticks and the electrostatic surface representation 527 
depicts charge. G) V1V2 mAb CDRH3 loops complexed with the V1V2 (magenta) and associated 528 
glycans (surface). H) VRC38.01, PG9, and CH03 interactions with V1V2 strand C. VRC38.01 529 
makes side-chain hydrogen bond contacts with K168 and K171 of strand C, N156 and S158 of 530 
strand B, and N133 and T135 of strand A. PG9 and CH03 make extensive main-chain parallel 531 
strand-strand interactions only with strand C. Side chain PG9 and CH03 contacts are shown in 532 
Figure S9B. I) Summary of V1V2 mAb contacts. Aligned V1V2 sequences are shown with their 533 
VRC38.01 sensitivities. VRC38.01, CH03 and PG9 contacts are shown as closed circles (side 534 
chain contacts), open circles (main chain contacts) and starred circles (both side chain and main 535 
chain contacts). Strands A to D, the N133, N156 and N160 glycans and the site of an engineered 536 
N-linked glycosylation insert between strands B and C (residues 165 and 166) placed at the 537 
approximate location of the N160 glycan of the neighboring protomer.  See also Figure S5. 538 
 539 
Figure 5. Breadth and residue-level requirements of VRC38.01 sensitivity. Prototype V1V2 540 
mAbs were color coded as in Figure 4. A) Sequences of VRC38.01-sensitive (IC50<50μg/ml) and 541 
-resistant (IC50>50μg/ml) strains of our 208-member virus panel (Table S1) were rendered as 542 
logo plots, the height of each residue corresponding to its frequency. Residues and sequons (gly) 543 
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linked with sensitivity (green) or resistance (red) with % conservation are shown. B) VRC38.01 544 
resistance mutations in descending order of prevalence, with red bars indicating the number of 545 
viruses containing each resistance mutation. Vertical red bar overlaps indicate strains with 546 
multiple resistance mutations. Gray bars indicate the number of viruses with unaccounted 547 
resistance mechanisms. C) Structural analysis of VRC38.01 resistance mutations. A common 548 
glycan at residue 130 clashes with the VRC38.01 light chain (left). A favorable electrostatic 549 
interaction is formed between Glu97 of the heavy chain and a positive residue at position 171 on 550 
gp120 (center). Tyr173 appears to favorably orient the N156 glycan (right). D) Effects of N130 551 
glycan knockin (KI) mutations on the V1V2 NAb sensitivity of viruses that naturally lack the N130 552 
glycan. IC50 ratios against the parent and each KI virus are indicated. Ratios >1 indicate 553 
increased sensitivity. Conversely, ratios of <1 indicate reduced sensitivity. E) Effects of N130 554 
glycan removal (KO) mutations on the V1V2 NAb sensitivity of viruses that naturally bear this 555 
glycan. IC50 ratios are shown as in (D). *Maximum neutralization (50g/ml) of the DU172.17 556 
mutant by VRC38.01 reached 47.8%, as compared to 0% for WT. Neutralization assays were 557 
repeated 2 times. See also Figures S. 558 
 559 
Figure 6. Structural maturation of the VRC38 lineage sequence. A) VRC38 phylogenetic tree 560 
branches were color-coded by their breadth against 31-member virus panel (Figure 1E). 561 
Computationally inferred intermediates are shown at nodes, with those leading to mature 562 
VRC38.01 shown in blue. S31D and S97E mutations are shown as they first appear. B) Heavy 563 
chain intermediate (upper set) and mature (lower set) sequences. In the upper set, intermediates 564 
leading to VRC38.01 are shown in blue. In the lower set, the 11 mature heavy chains are shown 565 
in descending order of breadth against the 31-member virus panel and are color-coded as in 566 
panel A. D31 and E97 contacts are boxed. C) Structures of germline-reverted (gHgL, grey), I1 567 
and I3 intermediates, and mature Ab complexed with WITO V1V2 (magenta). VRC38.01 heavy 568 
(yellow) and light (blue) chain V1V2 contacts are colored and shown in stick representation as 569 
they appear during maturation. D) Effects of reverting D31 and E97 residues to VRC38.01 inferred 570 
ancestor residues (S31 and S97) on mature VRC38.01 neutralization activity. Mutations, alone or 571 
in combination, were introduced into the VRC38.01 heavy chain, and co-expressed with the 572 
mature VRC38.01 light chain, then assessed for neutralization activity. Ratios of IC50s of WT 573 
VRC38.01 and mutant Abs are shown. Data are excluded for viruses in which both the WT and 574 
mutant Abs yielded IC50s>50µg/ml. E) Effects of mutating VRC38.09 S97 to E97. The heavy 575 
chain mutant was co-expressed with the mature VRC38.09 light chain and assessed for 576 
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neutralization. Ratios of IC50s of WT VRC38.09 and of the S97E mutant Ab are shown. 577 
Neutralization assays were repeated 2 times. See also Table S6. 578 
 579 
Figure 7. Fingerprint analysis suggests VRC38-like specificities are common in HIV-580 
infections. A) Predicted frequency (percent of plasma) of different bnAb specificities. Bars were 581 
colored per Ab specificity, with bar height corresponding to frequency. B) Frequency of paired 582 
bnAb specificities in samples with predicted multiple specificities. Circle diameter corresponds to 583 
bnAb specificity frequencies. Edge widths correspond to the frequencies of specificity pairs. 584 
 585 
STAR ★ METHODS 586 
 587 
CONTACT FOR REAGENT AND RESOURCE SHARING 588 
Further information and requests for resources and reagents should be directed to and will be 589 
fulfilled by the Lead Contact, James M. Binley (jbinley@SDBRI.org). 590 
 591 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  592 
 593 
Human Subjects 594 
Archived peripheral blood mononuclear cells (PBMCs) and sera derived from HIV-1 595 
infected donor N90 were used as a source of B cells. This donor signed informed consent and 596 
participated in NIAID protocols at the National Institutes of Health, Bethesda, MD (Doria-Rose et 597 
al., 2010; Georgiev et al., 2013; Migueles et al., 2002). At the time point studied, this donor was 598 
an antiretroviral therapy-naïve slow progressor who had been diagnosed 23 years prior and 599 
exhibited broad serum neutralization, with viral load of 8,216 copies/ml, and 912 CD4+ T-cells/µl 600 
(Wu et al., 2012). A cohort of serum samples from donors infected with various HIV-1 clades 601 
assembled from various sources, including the Center for the AIDS Programme of Research in 602 
South Africa (CAPRISA), the Center for HIV/AIDS Vaccine Immunology (CHAVI) and others, as 603 
previously published (Hraber et al., 2014) was used for fingerprinting analysis. Serum from 604 
chronically infected donor 1686 was previously shown to broadly neutralize via epitope(s) 605 
overlapping the CD4 binding site (Binley et al., 2008). PBMCs with no donor identifiers were also 606 
obtained from seronegative subjects for bait optimization. 607 
 608 
Cell Lines 609 
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Human embryonic kidney (HEK)-derived 293T, HEK 293S N-610 
acetylglucosaminyltransferase I-negative (GnTI-), and HeLa-derived TZM-bl cells were 611 
maintained in complete Dulbecco’s Modified Eagle Medium (herein referred to as cDMEM) 612 
containing high-glucose Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher, Waltham, 613 
MA), 1X Penicillin-Streptomycin (Pen Strep, Thermo Fisher) and 10% fetal bovine serum (FBS, 614 
Gemini Bio Products, West Sacramento, CA) at 37oC/5% CO2.  Canine thymus-derived 615 
CF2Th.CD4.CCR5 cells were maintained in DMEM containing 1X Pen Strep, L-glutamine, 500 616 
g/ml G418, 150 g/ml Hygromycin, and 10% FBS at 37oC/5% CO2.  FreeStyle 293F and 617 
Expi293F cells (both Thermo Fisher) were maintained in Freestyle 293 Expression Medium and 618 
Expi293 Expression Medium, respectively, at 37oC/10% CO2 with shaking at 120 RPM.  Human 619 
Burkitt’s B cell lymphoma-derived Ramos cells were maintained in either DMEM containing 15% 620 
FBS and 1X Pen Strep or Roswell Park Memorial Institute 1640 medium (RPMI 1640, Thermo-621 
Fisher) containing 10% FBS and 1X Pen Strep at 37oC/5% CO2. In some cases, Ramos cells 622 
were engineered to stably express mature B cell receptors (BCR) IgM versions of VRC01, 623 
PGT145, and PGT128.  624 
 625 
METHOD DETAILS 626 
 627 
Anti-HIV-1 Env Monoclonal Abs 628 
MAbs were obtained from the NIH AIDS Reagent Repository or from their originators. 629 
Further information can be found in the HIV Molecular Immunology Database 630 
(http://www.hiv.lanl.gov/) and in ref (Burton and Hangartner, 2016). MAbs included the following 631 
(originators given in parentheses): 2G12 (H. Katinger), directed to a glycan cluster on gp120 ; 632 
39F and CO11 (J. Robinson), directed to the gp120 V3 loop; b12 (D. Burton), VRC01, VRC07-633 
G54W, VRC13 (J. Mascola) and HJ16 (A. Lanzavecchia) directed to epitopes that overlap the 634 
CD4bs; PGT121, PGT125 and PGT128 (D. Burton) directed to epitopes involving the base of the 635 
V3 loop of gp120 and the N332 glycan; PG9, PG16, PGT145, PGDM1400 (D. Burton), CH01 and 636 
CH03 (B. Haynes) and CAP256.01-33 (J. Mascola), directed to quaternary, glycan-dependent 637 
V1V2 loop-directed epitopes; PGT151 (D. Burton), 35O22 (M. Connors), and 8ANC195 (M. 638 
Nussenzweig), directed to the gp120/gp41 interface; 10E8 (M. Connors), 2F5 and 4E10 (H. 639 
Katinger), directed to the gp41 membrane-proximal ectodomain region (MPER).  640 
 641 
Plasmids and Mutagenesis 642 
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 Plasmid pCAGGS was used to express JR-FL SOS E168K gp160∆CT (Moore et al., 643 
2006), featuring a 3 amino acid gp41 cytoplasmic tail, "SOS" mutations (A501C and T506C) to 644 
introduce a disulfide bond between gp120 and gp41 (Binley et al., 2000) and an E168K mutation 645 
to “knock in” V1V2 bnAb epitopes (Doores and Burton, 2010; Tong et al., 2012). Various Env 646 
expression plasmids were used to pseudotype viruses for neutralization assays and to express 647 
soluble gp140 glycoproteins, including uncleaved (UNC) YU2 gp140 foldon (gp140F) and 648 
BG505.DS.T332N.SOSIP.664 gp140 trimers (termed BG505 SOSIP trimers elsewhere for 649 
brevity) that feature the stabilizing 201C-433C disulfide (DS) mutation (Kwon et al., 2015). Some 650 
clones featured a C-terminal Avi tag (GLNDIFEAQKIEWHE) to enable biotinylation and 651 
fluororphore-streptavidin complexing (Doria-Rose et al., 2015). A codon optimized WITO strain 652 
V1V2 1FD6 scaffold was designed based on a previous construct (McLellan et al., 2011) and 653 
features an artificial N-terminal secretion signal (MRPTWAWWLFLVLLLALWAPARG), a C-654 
terminal HRV3C cleavage site (GLEVLFQGP) followed by an 8-His tag and an engineered N-655 
linked glycosylation site between strands B and C (residues 165 and 166) at the approximate 656 
location of the N160 glycan from the neighboring protomer. Env-deficient sub-genomic plasmids 657 
pNL4-3.Luc.R-E- and pSG3∆Env were described previously (Li et al., 2005). Plasmids pMV-2024 658 
and pMV-ERV express full-length SIVmac251 (BK28) and MLV Gag, respectively. Plasmid pMV-659 
0932 that expresses HIV-1 Rev was co-expressed whenever VLPs were produced using SIV or 660 
MLV Gag (Crooks et al., 2015). Plasmids pGag-GFP and pGag-RFP express full-length HIV-1 661 
p55 Gag fused to eGFP and mCherry fluorphores, respectively, that for convenience are referred 662 
to as GFP and RFP throughout this study (Gomez and Hope, 2006). MAb heavy and light chain 663 
genes (in many cases codon optimized) were inserted into pVRC8400 to express IgG in Freestyle 664 
293F or Expi293F cells, followed by protein A purification. In some cases, heavy chain plasmids 665 
were modified to add a C-terminal streptactin II tag 666 
(GGPGSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK), a HRV3C recognition site 667 
(LEVLFQ/GP) inserted after K235 of the heavy chain and/or M428L/N434S mutations (indicated 668 
by a "-LS" suffix) (Zalevsky et al., 2010), to improve neonatal Fc receptor binding and in vivo half 669 
life. 670 
 671 
Ramos-IgM Cell Line Production 672 
Ramos cells were engineered to stably express mature B cell receptors (BCR) IgM 673 
versions of VRC01, PGT145, and PGT128.by lentiviral transduction of the cells using FEEKW-674 
vectored light chain and IgM heavy chain-expressing lentiviruses.  BCR-positive cells were 675 
identified by staining with both PE-conjugated mouse anti-human-kappa/lambda (BD 676 
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Biosciences, San Jose, CA) and anti-human-IgM (Biolegend, San Diego, CA) by flow cytometry 677 
and sorted using a FACS Aria (BD Biosciences).  Cells were amplified, assessed for BCR 678 
expression as before, and resorted for highest-staining cells if needed. 679 
 680 
VLP Production 681 
 VLPs were produced by co-transfecting 293T or Freestyle 293F cells with plasmids 682 
expressing Env, Gag, and Rev (Crooks et al., 2015). Fluorescent VLPs were produced by also 683 
cotransfecting plasmids pGag-GFP or pGag-RFP. Two days later, supernatants were collected, 684 
filtered, precleared by centrifugation at 450Xg for 5 minutes, and concentrated either by tangential 685 
flow filtration or by centrifugation at 50,000Xg in a Sorvall SS34 rotor. "Trimer-VLPs" were made 686 
by digesting with 1 l each of 1mg/ml proteinase K, subtilisin, and trypsin, and 1 l of 2mg/ml 687 
chymotrypsin (Crooks et al., 2011; Tong et al., 2012). pNL4-3.Luc.R-E- based fluorescent VLPs 688 
were inactivated using 1mM aldrithiol (AT-2) before use as baits (Crooks et al., 2015). RFP-689 
labeled “Bald-VLPs” were produced by co-expressing pMV-2024 (expressing SIV Gag) and 690 
pGag-RFP plasmids. 691 
 692 
Soluble Env Protein Production 693 
Trimeric Env constructs were expressed in various types of 293 cells and then purified by 694 
previously published methods  (Bhiman et al., 2015; Doria-Rose et al., 2015; Stewart-Jones 695 
et al., 2016).  For BG505.T332N.SOSIP proteins used for flow cytometric cell sorting, Avi-tagged 696 
proteins were biotinylated using the BirA Biotin-Protein Ligase Bulk Reaction Kit (Avidity, LLC, 697 
Aurora, CO) under the following conditions and reagents from the kit:  25 l of 10X Biomix A, 25 l 698 
of 10X Biomix B, 20 g of BirA protein, and 180 l of Avi-tagged SOSIP protein, incubated for 5 699 
hours at 30oC with constant agitation.  The mixture was buffer exchanged into SOSIP buffer 700 
containing 5mM HEPES, 150mM NaCl, and 0.02% NaN3 in 30,000 MWCO Amicon Ultra-15 701 
centrifugal filter units (EMD Millipore) over 5 rounds of spinning at 3000Xg, 4oC.  Biotinylated 702 
SOSIP was then conjugated with streptavidin, R-phycoerythrin (SA-PE, Thermo Fisher) at a 1.17 703 
SA-PE:SOSIP weight ratio (determined empirically). Briefly, biotinylated SOSIP was mixed with 704 
1/5 the final volume of SA-PE and incubated for 20 minutes at 4oC with gentle rotation.  705 
Subsequent 1/5 increments of SA-PE were then added with 20-minute incubations in between 706 
each addition.  APC-conjugated YU2 gp140 foldon (gp140F) protein was biotinylated and 707 
conjugated to SA-allophycocyanin (SA-APC, Thermo Fisher) in the same manner at a 1.8 708 
gp140F:SA-APC weight ratio (determined empirically) 709 
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V1V2 regions of various strains (residues 126-196, HXB2 numbering) were scaffolded 710 
onto a core variant of protein G (PDB 1FD6) and were produced in HEK 293S GnTI- cells and 711 
purified over Ni-NTA superflow resin (Qiagen, Hilden, Germany), then digested with HRV3C 712 
(Novagen, Darmstadt, Germany) and purified over a 16/60 S200 size exclusion column (McLellan 713 
et al., 2011; Ross et al., 2001). 714 
 715 
HIV-1 Env-pseudotyped Virus Production 716 
Pseudoviruses for use in TZM-bl neutralization assays were produced in 293T cells by 717 
cotransfection of a pSG3∆Env backbone plasmid and a full HIV-1 Env gp160-encoding plasmid 718 
(Li et al., 2005).  Briefly, 2X106 cells in 20ml cDMEM were seeded in T75 flasks the day prior to 719 
cotransfection.  For transfection, 40 l of FuGene 6 reagent (Promega, Fitchburg, WI) was diluted 720 
into 800 l of room-temperature Opti-MEM I reduced serum medium (Thermo Fisher), followed 721 
by addition of 10 g of pSG3∆Env backbone plasmid.  3.3 g of HIV Env plasmid was then added 722 
to the mixture, mixed, and incubated for 30 minutes at room temperature. Transfection mixture 723 
was then added to media of previously seeded 293T cells in the T75 flask and then distributed 724 
evenly on cells.  The following day, media was replaced with 20ml fresh cDMEM.  Virus was 725 
harvested the following day by filtering cell supernatants with 0.45 m Steriflip units (EMD 726 
Millipore, Darmstadt, Germany) and aliquotted. 727 
Pseudoviruses for use in CF2 cell assays were produced in 293T cells by cotransfecting 728 
pNL4.3.Luc.R-E backbone plasmid and Env-expressing pCAGGS plasmid using 729 
polyethylenimine (PEI) Max (Polysciences, Warrington, PA).  Briefly, 5X106 cells were seeded on 730 
a 15cm tissue culture dish one day prior to transfection.  On the day of transfection, 10 g of 731 
pNL4.3.Luc.R-E and 10 g of Env plasmid were mixed in 2ml of serum-free DMEM.  40 l of 732 
1mg/ml PEI Max (DNA:PEI ratio 1:2) was added and incubated at room temperature for 30 733 
minutes.  11ml of cDMEM was then added to the transfection mixture.  293T cells were washed 734 
with PBS, and transfection mixture was added to the cells and distributed evenly.  Following a 2-735 
hour incubation at 37oC, culture dishes were washed with PBS, and 25ml of cDMEM was added 736 
to the cells for a 48-hour incubation at 37oC.  Following incubation, virus was harvested by 737 
pelleting cell culture supernatant at 450Xg and filtering supernatant through a 0.8 m filter. 738 
For pseudoviruses containing point mutations, mutations were introduced into full HIV-1 739 
Env-encoding plasmids using the QuickChange II Site-Directed Mutagenesis Kit (Agilent 740 
Technologies, Santa Clara, CA) according to the manufacturer’s directions.  For pseudoviruses 741 
produced under conditions containing kifunensine, 25 M kifunensine was added at the time of 742 
plasmid cotransfection and replenished during the media change. 743 
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 744 
B Cell Sorting of Env Trimer-specific Clones 745 
 Frozen PBMCs (~5X107 cells) were thawed in cDMEM containing 50 U/ml of benzonase 746 
(Novagen). For flow cytometric sorting, B cells were first enriched by negative magnetic bead 747 
selection using the Human B Cell Isolation Kit II (Miltenyi Biotec, San Diego, CA), then washed in 748 
PBS, resuspended in LIVE/DEAD® Fixable Violet Dead Cell Stain (Thermo Fisher) and incubated 749 
for 30 minutes at 4oC. Cells were washed once in PBS and multicolor staining was performed 750 
using a panel of fluorophore-labeled mAbs directed to CD3 (APC-Cy7, clone SK7), CD8 (Brilliant 751 
Violet 711, clone RPA-T8), CD14 (Brilliant Violet 605, clone M5E2), CD19 (PE-Cy7, clone HIB19) 752 
and human IgG (fluorescein isothiocyanate [FITC] or Alexa Fluor 680, both clone G18-145). All 753 
mAbs were obtained from BD Biosciences except for those directed to CD8 and CD14 (Biolegend) 754 
and the anti-IgG-Alexa 680 Ab (custom-conjugated at the Vaccine Research Center, National 755 
Institutes of Health, Bethesda, MD). Cells were also stained with fluorophore-tagged VLPs, 756 
BG505 SOSIP trimers or YU2 gp140F. All staining was performed at 4°C for 30 minutes, followed 757 
by two PBS/10% FBS washes and resuspension in PBS. Cells labeled as CD3-/CD8-/CD14-758 
/CD19+/IgG+/GFP+/RFP- memory B cells were gated for VLP stains, or as CD3-/CD8-/CD14-759 
/CD19+/IgG+/BG505 SOSIP trimer+/YU2 gp140F- for BG505 SOSIP trimer stains. Desirable cells 760 
were singly index-sorted on a FACS Aria sorter (BD Biosciences) into 96-well PCR plates 761 
(Denville Scientific, Holliston, MA) containing 20 l/well lysis buffer consisting of 1U/ l RNAse 762 
OUT (Thermo Fisher), 0.3125% Igepal CA-630, 1X SuperScript III First-Strand Buffer and 6.25 763 
mM dithiothreitol (DTT) provided with the Superscript III Reverse Transcriptase kit (Thermo 764 
Fisher). Data was collected using FACSDiva software (BD Biosciences). Indexed sort data was 765 
analyzed using FlowJo software (FlowJo, LLC, Ashland, OR). 766 
 767 
Single Cell RT-PCR of Ig Genes  768 
 RT-PCR amplification of IgG heavy and light chain genes was performed as described 769 
previously (Doria-Rose et al., 2015). 96-well plates containing single sorted cells were initially 770 
frozen at -80oC and thawed to maximize liberation of cellular mRNA.  Total mRNA in each well of 771 
the 96-well plates was reverse transcribed using 200U/well Superscript III reverse transcriptase 772 
(Thermo Fisher), 2 l of 10mM dNTP mix (Bioline, Taunton, MA) and 3 l of 150 ng/ul random 773 
hexamers (Gene Link, Hawthorne, NY) under the following cycling parameters:  42oC 10 min, 774 
25oC 10 min, 50oC 60 min, 94oC 5 min, and 4oC hold.  775 
First strand cDNA was amplified in a 2-step multiplex nested PCR in which the first step 776 
used either mixed -, -, or -chain-specific primers (listed in (Doria-Rose et al., 2015). 50 l - 777 
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chain amplification reactions were performed using the Qiagen HotStarTaq Plus DNA Polymerase 778 
Kit as follows (all reagents from HotStarTaq Plus kit unless otherwise noted):  1X Qiagen PCR 779 
Buffer, 200 M dNTP mix (Bioline), 500 M MgCl2, 1 l of 50 M 1st round forward primer mix (5’L-780 
Vk mix), 1 l of 25 M 1st round reverse primer (3’Ck 543), 2U HotStarTaq Plus, and 5 l of first-781 
strand cDNA, under the following cycling parameters: 95oC 5 min; 50 cycles of 95oC 30 sec, 58oC 782 
30 sec, 72oC 1min; 72oC 7 min; and 4oC hold.  40 l - chain and -chain amplification reactions 783 
were performed similarly as follows:  1X Qiagen PCR Buffer, 125 M dNTP mix (Bioline), 1.4mM 784 
MgCl2, 0.2 l of 50 M 1st round forward primer mix (G1, G2, or G3 mix for - chain and 5’L-VL-785 
RL mix for -chain), 0.2 l of 25 M 1st round reverse primer (3’CgCH1 for - chain and 3’Cl for 786 
- chain), 2U HotStarTaq Plus, and 3 l of first-strand cDNA.  -chains were amplified under the 787 
following cycling parameters: 94oC 5 min; 50 cycles of 94oC 30 sec, xoC 30 sec, 72oC 55 sec; 788 
72oC 10 min; and 4oC hold, where x = 54oC for G1 mix, 48oC for G2 mix, and 52oC for G3 mix.  789 
-chains were amplified under the following cycling parameters: 95oC 5 min; 50 cycles of 95oC 790 
30 sec, 50oC 30 sec, 72oC 1min; 72oC 7 min; and 4oC hold. 791 
The second multiplex PCR step used mixed chain-specific primers that were 792 
complementary to regions slightly upstream and downstream from the first step forward and 793 
reverse primers, respectively. 50 l -, - and - chain amplification reactions were performed 794 
using the Qiagen HotStarTaq Plus DNA Polymerase Kit as follows (all reagents from HotStarTaq 795 
Plus kit unless otherwise noted):  1X CoralLoad PCR Buffer, 200 M dNTP mix (Bioline), 1X Q 796 
Solution, 1 l of 50 M 2nd round forward primer mix (5’L-VH mix + 5xwl-VH mix for - chain, 5’L-797 
Vk-MS mix for - chain, and 5’L Vl mix for - chain), 1 l of 25 M 2nd round reverse primer 798 
(3’IgGint for - chain, 3’Ck 494 for - chain, and 3’XhoI Cl for - chain), 2U HotStarTaq Plus, 799 
and 3.5 l 1st round PCR product.  -chains were amplified under the following cycling 800 
parameters: 95oC 5 min; 50 cycles of 95oC 30 sec, 58oC 30 sec, 72oC 1min; 72oC 7 min; and 4oC 801 
hold.   -chains were amplified under the following cycling parameters: 95oC 5 min; 50 cycles of 802 
95oC 30 sec, 52oC 30 sec, 72oC 1min; 72oC 7 min; and 4oC hold. -chains were amplified under 803 
the following cycling parameters: 95oC 5 min; 50 cycles of 95oC 30 sec, 60oC 30 sec, 72oC 1min; 804 
72oC 7 min; and 4oC hold. 805 
10 l of each second round PCR product was loaded into 1% ethidium bromide-stained 806 
pre-cast gels (Embi Tec, San Diego, CA) and run at 120 volts.  Gels were visualized under 807 
ultraviolet light, and second round PCR products from wells where PCR-amplified bands were 808 
obtained were selected for sequencing by ACGT, Inc (Wheeling, IL).  Alignments of sequences 809 
to germline V-, (D-), and J-genes and junctional analyses were performed using IMGT/V-QUEST 810 
(www.imgt.org). Clones of interest were identified by several criteria, including substantial 811 
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germline mutations (>10%) indicating a history of affinity selection, long CDRH3 loops and by 812 
repeated recovery in separate wells. Selected PCR products were cloned into pVRC8400 to 813 
construct heavy chain- and light chain-expressing plasmids for mAb expression and purification. 814 
 815 
mAb and Fab Production 816 
mAbs were expressed by cotransfection of Expi293F or Freestyle 293F cells (Thermo 817 
Fisher) with heavy chain- and light chain-expressing plasmids according to the cell manufacturer’s 818 
directions.  Following a 6-day incubation, transfection mixtures were pelleted by centrifugation 819 
and filtered through 0.22 m Stericup filter units (EMD Millipore).  Filtered supernatant was applied 820 
to a column containing a 1ml bed of Protein A Sepharose Fast Flow (GE Healthcare, Chicago, IL) 821 
equilibrated with Pierce Protein A IgG Binding Buffer (Thermo Fisher).  The column was washed 822 
with Protein A IgG Binding Buffer, and mAb was eluted with Pierce IgG Elution Buffer (Thermo 823 
Scientific) and collected in a 1:10 volume of 1M Tris pH 8 solution.  Antibodies were buffer-824 
exchanged in PBS using 10,000 MWCO Amicon Ultra-15 centrifugal filter units (EMD Millipore) 825 
over three rounds of spinning. 826 
For Fab production, the cleavage site (GLEVLFQGP) for the 3C protease of human 827 
rhinovirus (HRV3C) was inserted into the hinge region of the Ab heavy chain expression plasmid.  828 
Following expression and purification of mAb, the protein was subjected to HRV3C protease.  829 
Products were purified by gel filtration, and Fab fragments were collected for use in assays. 830 
 831 
Biotinylation of mAbs 832 
 MAbs were biotinylated using EZ-Link Sulfo-NHS-Biotin (Thermo Fisher).  Briefly, mAb 833 
was concentrated to 2-2.5 mg/ml (200-250 l volume) and mixed with 15 l of 50mg/ml Blue 834 
Dextran.  MAb:Dextran mixture was applied to a Sephadex G25, NAP-5 column (GE Healthcare) 835 
previously washed 5X with 0.1M bicarbonate buffer (100mM NaHCO3, pH 8.4).  Antibody was 836 
eluted with 0.1M bicarbonate buffer, and the blue fraction containing mAb was collected.  EZ Link 837 
Sulfo-NHS-Biotin (prepared as a 10mg/ml solution with dimethylsulfoxide) was added at 80 g 838 
per 1mg mAb ratio and allowed to mix by rotating for 4 hours at room temperature.  Biotinylated 839 
mAb was then loaded onto a Sephadex G25, PD-10 desalting column (GE Healthcare) previously 840 
washed 5X with a storage buffer containing 10mM Tris, 150mM NaCl, 0.1% NaN3,pH 8.2.  MAb 841 
was eluted with storage buffer, and the blue fraction containing biotinylated mAb was collected. 842 
 843 
ELISAs with Recombinant VLPs, gp120 and gp140 844 
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Briefly, Immulon II plates were coated with either 20x concentrated VLPs (Tong et al., 845 
2012), 5µg/ml recombinant gp120 monomer, or 5µg/ml gp140 trimers overnight at 4C. Plates 846 
were washed with PBS twice and blocked. For VLP ELISA, blocking buffer was 4% BSA in 10% 847 
FBS/PBS, and for gp120 or gp140 ELISAs, blocking buffer was 4% milk in 0.05% Tween20/PBS. 848 
After 1h of blocking at room temperature and 2 washes with PBS or PBS containing 0.1% Tween 849 
20 (PBS-T), serially diluted sera or mAbs were added in the following reaction buffers: 2% BSA 850 
in 10%FBS/PBS for VLP ELISA and 2% milk in PBS-T for gp120 or gp140 ELISAs. Plates were 851 
incubated for 1 hour at 37oC followed by 2 PBS or PBS-T washes. Species-specific alkaline 852 
phosphatase anti-Fc conjugates (Accurate, Westbury, NY) diluted in the corresponding reaction 853 
buffers at 1:5,000 were then added and plates were incubated at 37oC for 30 minutes. After a 4X 854 
wash with distilled H2O, 50 l of SigmaFAST p-nitrophenyl phosphate tablets (Sigma, St. Louis, 855 
MO) dissolved in distilled H2O was added and incubated for 1 hour at room temperature in the 856 
dark. Reaction was stopped by adding 10 l of 3N NaOH and detected at 405nm. 857 
 ELISAs using SOSIP gp140 trimers, gp140F, gp120 monomers, and V1V2 scaffolds were 858 
performed on Reacti-Bind 96-well polystyrene plates (Pierce). Briefly, plates were coated with 859 
2 g/ml of monomer/trimer in PBS overnight at 4C. Following 6 washes with PBS-T and blocking 860 
for 1 hour at 37oC with B3T buffer (150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 3.3% FBS, 2% 861 
bovine serum albumin, 0.07% Tween 20, and 0.02% thimerosal), 5-fold serially diluted sera or 862 
mAbs were added in B3T buffer. After a 1-hour incubation at 37oC and 6 washes with PBS-T, 863 
plates were incubated with HRP-conjugated anti-human IgG, Fc  fragment-specific antibody 864 
(Jackson ImmunoResearch, West Grove, PA) diluted 1:10,000 in B3T buffer for 1 hour at 37oC.  865 
After 6 washes with PBS-T, SureBlue TMB Substrate (KPL, Gaithersburg, MD) was added, 866 
incubated for 10 minutes, and the reaction was stopped with 1N H2SO4 before measuring binding 867 
at 450nm.  868 
 Competitive VLP ELISAs was performed similarly to regular VLP ELISAs. Plates were 869 
coated, washed and blocked in the same manner. After blocking, plates were washed twice with 870 
PBS, and 25 l of competitor antibody was added at a fixed concentration. Following a 10-minute 871 
incubation at 37oC, titrated biotinylated or Strep II-tagged mAbs were added and incubated for an 872 
additional hour at 37oC. After 2 washes with PBS, conjugates were added as follows: 1:300-873 
diluted streptavidin-alkaline phosphatase (Vector, Burlingame, CA) for biotinylated antibodies or 874 
1:500-diluted streptactin-alkaline phosphatase (IBA Life Sciences, Goettingen, Germany) for 875 
Strep II-tagged antibodies.  Plates were washed with distilled H2O 4 times, 50 l of SigmaFAST 876 
p-nitrophenyl phosphate tablets (Sigma) dissolved in distilled H2O water was added, and plates 877 
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were incubated for 1 hour at room temperature in the dark. Reaction was stopped by adding 10 l 878 
of 3N NaOH before measuring binding at 405nm. 879 
 880 
Measuring Probe Binding to mAb-Coated Beads 881 
 CompBead Anti-Mouse Ig,  (BD Biosciences) 882 
were coated with mAbs for antigenic analysis of HIV-1 Env proteins and trimers.  Briefly, 1ml of 883 
particles (beads) was pelleted at 1000Xg for 5 minutes, and supernatant was aspirated.  Beads 884 
were resuspended in 1ml 0.5% bovine serum albumin (BSA) in PBS.  1 g of Purified Mouse Anti-885 
Human Ig  Light Chain antibody (BD Biosciences) was added and allowed to incubate for 30 886 
minutes at room temperature.  2ml of 0.5% BSA/PBS was added, beads were pelleted at 1000Xg 887 
for 5 minutes, and supernatant was aspirated.  Beads were resuspended in 1ml of 0.5% 888 
BSA/PBS, and 1 g of mAb was added, mixed, and incubated for 30 minutes at room temperature.  889 
2ml of 0.5% BSA/PBS was added, beads were pelleted at 1000Xg for 5 minutes, and 890 
supernatants were aspirated.  Beads were resuspended in 1ml 0.5% BSA/PBS for short-term 891 
storage of up to 1 week at 4oC.  For staining, 50 l of antibody-coated beads were mixed with 892 
different amounts of streptavidin-conjugated HIV-1 Env protein or trimer, incubated with 30 893 
minutes at 4oC, and washed with 3ml of PBS.  Beads were pelleted at 1000Xg for 5 minutes, 894 
supernatants were aspirated, and beads were resuspended in 300-500 l PBS for flow cytometric 895 
analysis. 896 
  897 
Neutralization Assays Using TZM-bl Cells 898 
 10 l of five-fold serially diluted mAbs or patient serum in cDMEM was incubated with 40ul 899 
of diluted HIV-1 Env-pseudotyped virus and incubated for 30 minutes at 37oC in a 96-well tissue 900 
culture plate.  20 l of TZM-bl cells (10,000 cells/well) with or without 70 g/ml DEAE-Dextran 901 
was then added and incubated overnight at 37oC.  Each experiment plate also had a column of 902 
cells only (no Ab or virus) and a column of virus only (no Ab) as controls for background TZM-bl 903 
luciferase activity and maximal viral entry, respectively.  The following day, all wells received 904 
130 l of fresh cDMEM and were incubated overnight at 37oC.  The following day, media was 905 
aspirated from wells, and 50ul of 1X Cell Culture Lysis Reagent (Promega) in distilled H2O was 906 
added to cells.  Lysates were shaken at 600RPM for 15 minutes, and 30 l of lysate was 907 
transferred to OptiPlate black plates (Perkin Elmer).  Luminometry was performed on a Perkin 908 
Elmer Model #1420-061 luminometer using the Promega Luciferase Assay System reagent 909 
(reconstituted in buffer provided with the kit, equilibrated to room temperature).  Percent 910 
neutralization is determined by calculating the difference in average RLU between virus only wells 911 
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(cells + virus column) and test wells (cells + serum/Ab sample + virus), dividing this result by the 912 
average RLU of virus only wells (cell + virus column) and multiplying by 100.  Background is 913 
subtracted from all test wells using the average RLU from the uninfected control wells (cells only 914 
column) before calculating the percent neutralization. Neutralizing serum antibody titers are 915 
expressed as the serum dilution/antibody concentration required to achieve 50% neutralization 916 
and calculated using a dose-response curve fit with a 5-parameter nonlinear function. 917 
 918 
Neutralization Assays Using CF2 Cells 919 
Neutralization assays using CF2 cells were performed as described previously (Crooks 920 
et al., 2015). On the day prior to the assay, 96 well plates were seeded with 200 l of 921 
CF2Th.CD4.CCR5 cells at 1x105/ml per well.  On the day of the assay, virus was incubated with 922 
serially diluted mAbs or serum for 1 hour at 37 oC. The virus:antibody/serum mixture was then 923 
added to plates seeded with CF2 cells, spinoculated at 300Xg for 15 minutes, and incubated for 924 
3 days at 37 oC. Luciferase activity was measured using the Promega Luciferase Assay System 925 
reagent. 926 
 927 
HEp-2 Cell Staining   928 
             Autoreactivity staining assays were performed on HEp-2 cells per the manufacturer 929 
recommendations (Zeus Scientific, Branchburg, NJ). MAbs were diluted to 50 and 25 g/ml using 930 
SAVe Diluent. 20 l of the appropriate dilution was coated onto cells fixed on the slide and 931 
incubated for 30 minutes at room temperature in a humidified chamber. Slides were rinsed in 1X 932 
PBS, washed twice in 1X PBS in Coplin jars for 3-5 minutes and then stained with 20 l of FITC-933 
conjugated secondary antibody for 30 minutes in a humidified chamber. Slides were rinsed in 1X 934 
PBS, washed twice in 1X PBS in Coplin jars for 3-5 minutes and mounted with 15 l of mounting 935 
media per well and a cover glass (Thermo Scientific). Slides were imaged on a Nikon Eclipse 936 
E800 microscope at 20X in the RGB mode for 2 seconds using SPOT 5.0 software (SPOT 937 
Imaging, Sterling Heights, MI). VRC01, 4E10, VRC07-523 and VRC07-G54W were used as 938 
control mAbs for staining and given a score of 0, 1, 2 and 3 respectively based on their staining 939 
intensity. Test antibodies were assigned scores based on visual comparisons of staining intensity 940 
to the control antibodies. 941 
 942 
Cardiolipin ELISA  943 
            MAb binding to cardiolipin was tested by ELISA per the manufacturer’s protocol (Inova 944 
Diagnostics, San Diego, CA). Starting at 100 g/ml, mAbs were tested in a 3-fold series. Assays 945 
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were validated using positive and negative controls and standards provided in the kit. OD values 946 
were converted to IgG anti-phospholipid (GPL) units by linear regression. 4E10 and VRC01 were 947 
used as additional positive and negative controls. Cardiolipin binding was scored as follows: no 948 
binding for <15 GPL, indeterminate for 15-20 GPL, low positive for 20-80 GPL and high positive 949 
for >80 GPL. 950 
 951 
Genetic Clustering and Phylogenetic Analysis 952 
 MAb sequences were aligned by ClustalOmega, followed by ClustalW-Phylogeny and 953 
Dendroscope (Huson et al., 2007) to generate and display the phylogenetic tree. MAb lineages 954 
were inferred using Cloanalyst (http://www.bu.edu/computationalimmunology). Briefly, DNA 955 
Maximum Likelihood (DNAML) from the Phylip molecular evolution suite was used to find the 956 
maximum likelihood tree using the  and  chains together, with mutation rates differing by chain 957 
and varying by site. The inferred ancestor (IA) and intermediates were determined by computing 958 
the Bayesian posterior probability over all possible sequences representing unmutated 959 
immunoglobulin variable-region gene rearrangements. 960 
 961 
Blue Native PAGE-Western Blot 962 
 VLPs were solubilized in 0.12% Triton X-100 in 1 mM EDTA/1.5 M aminocaproic acid with 963 
a protease inhibitor cocktail (P-2714; Sigma). An equal volume of 2X sample buffer (100 mM 964 
morpholinepropanesulfonic acid, 100 mM Tris-HCl, pH 7.7, 40% glycerol, and 0.1% Coomassie 965 
blue) was added. Samples were then loaded onto a 4-12% Bis-Tris NuPAGE gel (Thermo Fisher) 966 
and separated at 4°C for 3 hours at 100V. The gel was then blotted onto polyvinylidene difluoride 967 
and destained with a solution containing 35% methanol and 10% acetic acid followed by 100% 968 
methanol until blue stain was removed. The blot was blocked using 4% nonfat milk in PBS for 1 969 
hour at room temperature and probed with mAbs 2G12, b12, 39F, 2F5 and 4E10 at 1µg/ml each.  970 
The blot was developed with anti-human Fc alkaline phosphatase conjugate (Jackson 971 
ImmunoResearch, West Grove, PA) diluted 1:5,000 in 2% milk in TBS-T followed by SigmaFast 972 
BCIP/NBT substrate (Sigma).  973 
 In BN-PAGE “shift” assays (Moore et al., 2006; Tong et al., 2012) mAbs were incubated 974 
at 37C for 1 hour with 12.5 g gp120 equivalents of Env that was liberated from VLPs by adding 975 
1% Triton X-100. Complexes were then resolved by BN-PAGE-Western blot as above and probed 976 
with a cocktail of biotinylated mAbs (b12, 2G12 and 4E10) followed by a streptavidin-alkaline 977 
phosphatase conjugate and BCIP/NBT.  978 
 979 
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Negative-stain EM 980 
 VRC38 IgG or monovalent Fab was incubated overnight in Tris-buffered saline (TBS) 981 
containing 50mM Tris, 150mM NaCl, pH 7.4) at room temperature with BG505 or B41 SOSIP.664 982 
gp140 trimers (Pugach et al., 2015) at a 10X molar excess of mAb. Samples were then diluted 983 
to ~0.01mg/ml in TBS and applied to a plasma-cleaned carbon-coated Cu400 mesh grid (Electron 984 
Microscopy Sciences, Hatfield, PA) for about 10 seconds. Nano-W stain (NanoProbes, Inc., 985 
Yaphank, NY) was applied for 7 seconds, blotted with filter paper, and a fresh drop applied for an 986 
additional 15 seconds before blotting. Image collection and data processing was performed as 987 
described elsewhere (de Taeye et al., 2015) on either an FEI Tecnai T12 microscope (2.05 988 
Å/pixel; 52,000X magnification) or FEI Talos microscope (1.57Å/pixel; 92,000X magnification). 2D 989 
class averages for these datasets and other data (Doria-Rose et al., 2014; Julien et al., 2013; 990 
Sok et al., 2014) were generated by Iterative MSA/MRA (Ogura et al., 2003) or SPARX ISAC 991 
methods (Yang et al., 2012). Figures were created using UCSF Chimera (Petterson et al., 2004).  992 
 993 
Structural Analysis 994 
 To form VRC38-1FD6-WITO-V1V2 complexes, 3mg of purified VRC38.01 HRV3C mutant 995 
IgG was bound to 750 ml Protein A Plus Agarose (Pierce) in a disposable 10ml column. 10mg of 996 
V1V2 scaffold, produced in GnTI- cells, was then added. Misfolded or improperly glycosylated 997 
scaffold remained unbound to Ab and was flushed with 5 column volumes of PBS. The column 998 
was capped and 20 l of HRV3C protease at 2U/ l was added in 1ml of PBS. After 2 hours at 999 
room temperature, the resin was drained, the eluate collected and passed over a 16/60 S200 1000 
column in buffer containing 5mM HEPES 7.5, 50mM NaCl, and 0.02% NaN3. VRC38.01–1FD6-1001 
WITO-V1V2 complex fractions were pooled and concentrated to 10mg/ml. 1002 
 Samples of monovalent VRC38.01 Fab, both unliganded and in complex with 1FD6-1003 
WITO-V1V2, were screened for crystallization using 572 conditions from Hampton, Wizard and 1004 
Precipitant Synergy screens using a Cartesian Honeybee and a mosquito crystallization robot 1005 
with 0.1 l of reservoir solution and 0.1 l of protein solution per condition. Crystals for VRC38.01 1006 
Fab obtained in 14% PEG400, 13% PEG8000, 0.1M Tris pH 8.5, 0.1M MgCl2 were flash-frozen 1007 
in liquid nitrogen with no cryoprotectant. Crystals of VRC38.01–1FD6-WITO-V1V2 obtained in 1008 
27% isopropanol, 0.1M imidazole pH 6.5 and 10% PEG8000 were flash-frozen in liquid nitrogen 1009 
in mother liquor supplemented with 20% 2-methyl-2,4-pentanedial (MPD). Data were collected at 1010 
1.00Å using the SER-CAT beamline ID-22 of the Advanced Photon Source, Argonne National 1011 
Laboratory (Lemont, IL). 1012 
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 Diffraction data were processed with the HKL2000 suite 6 (HKL Research, Inc., 1013 
Charlottesville, VA). A molecular replacement solution for unliganded VRC38.01 obtained with 1014 
Phenix (www.phenix-online.org) contained one Fab molecule per asymmetric unit in space group 1015 
P21221. The structure of the complex contained one Fab bound to a 1FD6–WITO-V1V2 monomer 1016 
in space group P3221. Model building was carried out using COOT software (https://www2.mrc-1017 
lmb.cam.ac.uk/personal/pemsley/coot/), and was refined with Phenix. Final data collection and 1018 
refinement statistics are shown in supplemental Table 1. The Ramachandran plot determined by 1019 
Molprobity (http://molprobity.biochem.duke.edu) shows 98.4% of all residues in favored regions 1020 
and 100% of all residues in allowed regions for the unliganded Fab structure and 92.8% of all 1021 
residues in favored regions and 99.2% of all residues in allowed regions for the complex structure. 1022 
 1023 
 1024 
Biolayer Interferometry 1025 
 BG505.T332N.His8x SOSIP.664 was coated onto a His1K Octet biosensor surface 1026 
(ForteBio, Menlo Park, CA) at 10 g/ml for 60 seconds, followed by a baseline for 60 seconds and 1027 
an association step with saturating concentrations of various mAbs (50 g/ml of IgG for 30 minutes 1028 
or 50 g/ml Fab fragments for 45 minutes). Response values from the last 30 seconds of the 1029 
association step were averaged to obtain the saturation binding.  Mean binding response and 1030 
standard deviations from 3 independent experiments were plotted against the known number of 1031 
binding sites occupied by each mAb or mAb cocktail by regression analysis to generate a standard 1032 
curve for trimer occupancy. 1033 
 1034 
Surface Plasmon Resonance Analysis 1035 
Affinities and kinetics of binding of VRC38.01 Fab and IgG to BG505 DS-SOSIP.664 1036 
soluble trimer were assessed by surface plasmon resonance on a Biacore S-200 (GE Healthcare) 1037 
at 25°C with buffer HBS-EP+ (10mM HEPES, pH 7.4, 150mM NaCl, 3mM EDTA, and 0.05% 1038 
surfactant P-20). Ab was first immobilized onto two flow cells on a CM5 chip at ~800 response 1039 
units (RU) with standard amine coupling protocol (GE Healthcare). PGT145 IgG was immobilized 1040 
as a control to ensure trimer fidelity with BSA immobilized in the reference channel. Trimer, at 1041 
two-fold dilutions starting from 40nM were injected at a flow rate of 50  for 4 minutes 1042 
and allowed to dissociate for 6 minutes. The cells were regenerated with 100 l injections of 3.0M 1043 
MgCl2 at a flow rate of 50 l/min. Sensorgrams of the concentration series were corrected with 1044 
corresponding blank curves and fitted globally with Biacore S200 evaluation software (GE 1045 
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Healthcare) using a 1:1 Langmuir model of binding to highlight the apparent change in affinity 1046 
from Fab to IgG.  1047 
 1048 
Isothermal Titration Calorimetry 1049 
Isothermal titration calorimetry (ITC) was performed using the ITC200 microcalorimeter 1050 
system (MicroCal Inc., Malvern, Worcestershire, United Kingdom). Proteins were dialyzed against 1051 
filtered PBS before use.  The concentration of BG505 native, flexibly linked (NFL) trimer (Sharma 1052 
et al., 2015) in the sample cell was approximately 25 M, and that of VRC38.01 Fab in the syringe 1053 
was approximately 5 M.  Reactions were carried out at 37C, as previously described (Wu et al., 1054 
2010). Briefly, BG505 NFL trimer was titrated to saturation by stepwise addition of 2 l ligand in 1055 
the syringe at 120-second intervals at 37oC.  The heat evolved upon each injection was obtained 1056 
from the integral of the calorimetric signal.  The values of enthalpy ( H) and entropy ( S) were 1057 
obtained by fitting the data to a nonlinear least-squares analysis with Microcal ORIGIN software 1058 
using a single-site binding model. 1059 
 1060 
Neutralization Fingerprinting Analysis 1061 
Published neutralization data for a set of ~200 donor plasma samples (Hraber et al., 2014) 1062 
was analyzed by using a next-generation neutralization fingerprinting algorithm (Doria-Rose et 1063 
al., 2017). For a given sample, the approach compares a polyclonal neutralization pattern of a set 1064 
of diverse viral strains to the neutralization patterns (or fingerprints) of a reference set of broadly 1065 
neutralizing mAb specificities, to obtain an estimate of the contribution of each of the reference 1066 
specificities to polyclonal neutralization (Doria-Rose et al., 2017; Georgiev et al., 2013). 1067 
Reference broadly neutralizing antibodies were used as previously described (Pancera et al., 1068 
2014), with the VRC38 fingerprint as a separate category. We applied computational quality 1069 
control metrics for filtering out plasma samples for which the predictions were deemed unlikely to 1070 
be accurate. Specifically, these included metrics for: (i) predicting the presence of dominant novel 1071 
specificities and (ii) computing a confidence score associated with the computational predictions 1072 
for each given sample (Doria-Rose et al., 2017). Through this process, the initial set of samples 1073 
was reduced to 80 samples, which were used for the analysis of Ab specificity frequency. Samples 1074 
were predicted to have between 1 and 3 specificities from the reference set, and the overall 1075 





QUANTIFICATION AND STATISTICAL ANALYSIS 1080 
 For all mAb/serum pseudovirus neutralization assays (Figures 1E, 6D, and 6E; 1081 
Supplemental Figures S2A, S3B, S4A, S5B, S5F, S6A, S7E, and S7F; and Supplemental Tables 1082 
1, 3, and 5), data were fitted to a 5-parameter asymmetric nonlinear regression model to obtain 1083 
the IC50, or concentration of mAb/dilution of serum needed to obtain 50% neutralization against 1084 
a given pseudovirus.  For neutralization assays in which a fold-change in IC50 imparted by a 1085 
particular virus mutant, virus treatment, or binding stoichiometry (e.g., IgG vs. Fab) was reported 1086 
(Figures 6D and 6E; Supplemental Figures S4A, S5B, S5F, and S7E; and Supplemental Tables 1087 
3 and 5), the IC50 obtained for one virus/assay condition was divided by the IC50 obtained for 1088 
the other virus/assay condition, as indicated in the figure legends and y-axes of data graphs. All 1089 
neutralization assays were repeated at least 2 times, and data shown are from representative 1090 
experiments.   1091 
Multiple binding assays were performed to investigate VRC38.01 binding to HIV-1 Env 1092 
trimers and monomers.  All ELISAs (Figures 2A, 2B, and 2C; and Supplemental Figures S2C, 1093 
S2D, S2F, and S3A) were repeated at least two times, and curves shown are from representative 1094 
experiments.  BLI measurements (Supplemental Figure S4D) were taken over 3 independent 1095 
experiments, and the means and standard deviations of binding values were plotted.  Binding 1096 
stoichiometry of VRC38.01 IgG and Fab were interpolated from a standard linear regression 1097 
equation (indicated in the plots) derived from the BLI response data (nm) plotted against number 1098 
of known IgG/Fab binding sites per trimer.  Association and dissociation kinetics derived from 1099 
SPR data (Supplemental Figure S4B) were fitted to a 1:1 Langmuir model using Biacore S200 1100 
software, and data from a representative of 3 independent experiments is shown.  For ITC, 1101 
enthalpy and entropy values were interpolated from a nonlinear least-squares analysis using 1102 
Microcal ORIGIN software using a single-site binding model, and results shown are a 1103 
representative of 3 independent experiments. 1104 
 1105 
DATA AND SOFTWARE AVAILABILITY 1106 
 The sequences for VRC38.01-VRC38.14 heavy chains and VRC38.01-VRC38.11 light 1107 
chain have been deposited in GenBank under ID codes KY905214-KY905227 and KY905228-1108 
KY905238, respectively.  The crystal structures for unliganded N90-VRC38.01 Fab and V1V2-1109 
scaffold complex have been deposited in PDB under ID codes 5EWI and DDD, respectively. 1110 
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 1112 
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